Kinase Inhibitor [EPC]

367901 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS PALBOCICLIB ACALABRUTINIB AXITINIB LAROTRECTINIB VANDETANIB ABEMACICLIB AFATINIB AVAPRITINIB BRIGATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 43437
1 FATIGUE 33992
2 DIARRHOEA 30845
3 NAUSEA 22192
4 OFF LABEL USE 21461
5 RASH 14631
6 MALIGNANT NEOPLASM PROGRESSION 13780
7 ASTHENIA 13648
8 DECREASED APPETITE 13443
9 DYSPNOEA 13075
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 235 0.8736
1 CYTOGENETIC ANALYSIS ABNORMAL 390 0.5111
2 NEOPLASM PROGRESSION 11761 0.4688
3 ACQUIRED GENE MUTATION 392 0.4434
4 CHRONIC MYELOID LEUKAEMIA RECURRENT 155 0.3944
5 TRANSPLANT DYSFUNCTION 496 0.3749
6 CARBOHYDRATE ANTIGEN 15-3 INCREASED 158 0.3503
7 HAEMATOCRIT ABNORMAL 306 0.3319
8 NON-SMALL CELL LUNG CANCER 904 0.3277
9 TUMOUR MARKER INCREASED 989 0.3129
See all enriched reactions for Kinase Inhibitor [EPC]